Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

GRAIL’s Galleri® Multi-Cancer Early Detection Blood Test Results in Prostate Cancer Published in JCO Precision Oncology

NextEdge Admin

30 Aug 2024

2 min 19 sec

Prostate cancer,Oncology,Precision oncology

GRAIL, Inc. recently published findings in JCO Precision Oncology highlighting the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer. The study shows that Galleri effectively screens for aggressive prostate cancers while minimizing the risk of overdiagnosis of indolent, slow-growing cases. The data, drawn from the Circulating Cell-free Genome Atlas (CCGA) and PATHFINDER studies, included 420 prostate cancer patients. Results demonstrated that 93% of detected cases were intermediate or high-grade cancers, with 67% at stage III or IV. The cancer signal origin (CSO) prediction accuracy for prostate cancer was over 90%.

The test's sensitivity for early-stage prostate cancers (stages I and II) was 4.2%, reflecting the low shedding tumor fraction typical in these stages. Importantly, the Galleri test did not detect any low-grade cancers and identified only a small percentage of intermediate-grade and early-stage cancers. These findings suggest that the Galleri test can identify biologically significant prostate cancers that require treatment without exacerbating the problem of overdiagnosis.

Dr. Brandon Mahal, lead author and radiation oncologist at Sylvester Comprehensive Cancer Center, emphasized that these results demonstrate the potential of MCED tests like Galleri in population-based screening programs. Dr. Eric Klein, Distinguished Scientist at GRAIL, highlighted the high accuracy of the CSO prediction, underscoring the need for prompt diagnostic evaluation when a prostate cancer signal is detected. These findings affirm Galleri’s utility in enhancing prostate cancer screening while mitigating unnecessary treatment.